Pharmacological modulation of Th17

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 3, Issue 2, 2009, Pages 149-156

  De Sanctis, Juan B ^a   Garmendia, Jenny V ^a   Moreno, Dolores ^b   Larocca, Nancy ^b   Mijares, Michael ^b,c   Di Giulio, Camilo ^c   Salazar Bookaman, Margarita ^c   Wojewodka, Gabriella ^d   Radzioch, Danuta ^d  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^b Experimental Medicine Institute   (Venezuela)

^c UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Allergic diseases; Autoimmune diseases; IL 17; IL 17 receptors; Inflammation; Retinoid orphan receptors; Retinoids; Th 1; Th 17; Th 2

Indexed keywords

ALITRETINOIN; APILIMOD MESYLATE; AZITHROMYCIN; CH 223191; DEXAMETHASONE; ETANERCEPT; FENRETIDINE; FINGOLIMOD; IMMUNOMODULATING AGENT; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 17 INHIBITOR; INTERLEUKIN 17 RECEPTOR ANTIBODY; INTERLEUKIN 23; LYCOPENE; MACROLIDE; METHOTREXATE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; PREDNISOLONE; PROTEIN P40 ANTIBODY; RAPAMYCIN; RESOLVIN E1; RETINOIC ACID; RETINOID; SIMVASTATIN; TAMIBAROTENE; TARAZOTENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIALLERGIC AGENT; CYTOKINE;

ALLERGIC ASTHMA; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL TRIAL; COMMON VARIABLE IMMUNODEFICIENCY; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TH17 CELL; ULCERATIVE COLITIS; UVEORETINITIS; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; HELPER CELL; HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTI-ALLERGIC AGENTS; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; HYPERSENSITIVITY; INTERLEUKIN-17; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 68949186311     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221309788489814     Document Type: Article

References (94)

1. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009; [Epub ahead of print].
2. Romagnani S, Maggi E, Liotta F, Cosmi L, Annunziato F. Properties and origin of human Th17 cells. Mol Immunol 2009; [Epub ahead of print].
3. Ivanov S, Lindén A. Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci 2009; 30: 95-103.
4. Ghilardi N, Ouyang W. Targeting the development and effector functions of Th17 cells. Semin Immunol 2007; 19: 383-393.
5. Chen Z, O'Shea JJ. Th17 cells: A new fate for differentiating helper T cells. Immunol Res 2008; 41: 87-102.
6. Boniface K, Blom B, Liu YJ, de Waal Malefyt R. From interleukin-23 to T-helper 17 cells: Human T-helper cell differentiation revisited. Immunol Rev 2008; 226: 132-146.
7. Chen Z, Laurence A, O'Shea JJ. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin Immunol 2007; 19: 400-408.
8. Awasthi A, Murugaiyan G, Kuchroo VK. Interplay between effector Th17 and regulatory T cells. J Clin Immunol 2008; 28: 660-670.
9. Lee YK, Turner H, Maynard CL, et al. Late developmental plasticity in the T helper 17 lineage. Immunity 2009; 30: 92-107.
10. Cosmi L, De Palma R, Santarlasci V, et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med 2008; 205: 1903-1916.
11. Chang SH, Dong C. IL17F: Regulation, signaling and function in inflammation. Cytokine 2009; 46(1): 7-11.
12. Stockinger B, Veldhoen M, Martin B. Th17 T cells: Linking innate and adaptive immunity. Semin Immunol 2007; 19(6): 353-361.
13. Ivanov II, Zhou L, Littman DR. Transcriptional regulation of Th17 cell differentiation. Semin Immunol 2007; 19: 409-417.
14. Dardalhon V, Korn T, Kuchroo VK, Anderson AC. Role of Th1 and Th17 cells in organ-specific autoimmunity. J Autoimmun 2008; 31: 252-256.
15. McGeachy MJ, Cua DJ. The link between IL-23 and Th17 cellmediated immune pathologies. Semin Immunol 2007; 19: 372-376.
16. Stumhofer JS, Silver J, Hunter CA. Negative regulation of Th17 responses. Semin Immunol 2007; 19: 394-399.
17. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007; 148: 32-46.
18. Kawaguchi M, Takahashi D, Hizawa N, et al. IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J Allergy Clin Immunol 2006; 117: 795-801.
19. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 2008; 226: 57-79.
20. Dragon S, Saffar AS, Shan L, Gounni AS. IL-17 attenuates the antiapoptotic effects of GM-CSF in human neutrophils. Mol Immunol 2008; 45: 160-168.
21. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28: 454-467.
22. Aujla SJ, Dubin PJ, Kolls JK. Th17 cells and mucosal host defense. Semin Immunol 2007; 19: 377-382.
23. Koenders MI, Joosten LA, van den Berg WB. Potential new targets in arthritis therapy: Interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 2006; 65(Suppl 3): iii29-iii33.
24. Guilbault C, Wojewodka G, Saeed Z, et al. Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide. Am J Respir Cell Mol Biol 2008 [Epub ahead of print].
25. De Sanctis JB, Garmendia JV, Radzioch A, Radzioch D. New frontiers in the therapeutic management of transplant rejection. Curr Pharm Des 2006; 12: 2383-2395.
26. González-Alvaro I, Ortiz GAM, Domínguez-Jiménez C, Aragón-Bodi A, Díaz-Sánchez B, Sánchez-Madrid F. Inhibition of TNF and IL-17 production by leflunomide involves the JAK/STAT pathway. Ann Rheum Dis 2008 [Epub ahead of print].
27. Zhang C, Zhang J, Yang B, Wu C. Cyclosporin A inhibits the production of IL-17 by memory Th17 cells from healthy individuals and patients with rheumatoid arthritis. Cytokine 2008; 42: 345-352.
28. Ouaked N, Mantel PY, Bassin C, et al. Regulation of the foxp3 gene by the Th1 cytokines: The role of IL-27-induced STAT1. J Immunol 2009; 182: 1041-1049.
29. Shi, Y., Ruben, S.M.: US20026482923 (2002).
30. Kastelein, R. A., McClanahan, T. K., Murphy, E.: WO2005108616 (2005).
31. Mohler, K.M.: US20046793919 (2004).
32. Shi, Y., Ruben, S.M.: US20056849719 (2005).
33. Allan, B., Chow, C.K., Huang, L., Liu, L., Lu, J., Ng, K., Tetreault, J.W., Werner, A.G.: US20080269467 (2008).
34. Medlock, E., Yeh, R., Silbiger, S.M.: US20067094566B2 (2006).
35. Yao, Z., Spriggs, M.K., Fanslow, W.: US20036680057 (2003).
36. Haudenschild, D., Rose, L., Moseley, T., Reddi, A.H. US20040171109 (2004).
37. Rixon, M.W., Gao, Z., Levin, S.D., Stevens, B.L.: WO2007117762 (2007).
38. Yao, Z., Spriggs, M.K., Fanslow, W.: US20087432237 (2008).
39. Capon, D.J., Lasky, L.A.: US20087432357 (2008).
40. Adams, R., Popplewell, A.G., Rapecki, S.E., Tickle, S.P.: WO2006054059 (2006).
41. Chen, J., Filvaroff, E., Fong, S., Goddard, A., Godowski, P., Grimaldi, C., Gurnaey, A., Li, H., Hillan, K., Tumas, D., van Lookeren, M., Vandeln, R., Watanabe, C., Williams, P.M., Wood, W.I., Yashura, D.: US20036579520 (2003).
42. Rosen, C., Komatsoulis, G., Baker, K.P., Birse, C.E., Soppet, D.R., Olsen, H.S., Moore, P.A., Wei, P., Ebner, R., Duan, D.R., Shi, Y., Choi, G.H., Fiscella, M., Ni, J.: WO2002022654 (2002).
43. Lian, S.C., Fouser, L.A., O'Toole, M.: WO2007149814 (2007).
44. Presnell, S.R., Levin, S.D., Lewis, K.E., Mabry, G.R., Jaspers, S.R., Huber, M.J.: US20080299129 (2008).
45. Cua, D., Kastelen, R.A., Tsai, V.T., Caspi, R., Phylis, S., Luger, D.: WO2007027761 (2007).
46. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-IL-12 Crohn's Disease Study Group. Anti-IL-12 Crohn's Disease Study Group Antiinterleukin-12 antibody for active Crohn's disease. N Engl J Med 2004; 351: 2069-2079.
47. Fuss IJ, Becker C, Yang Z, et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 2006; 12: 9-15.
48. Gottlieb AB, Cooper KD, McCormick TS, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody administered subcutaneously in subjects with plaque psoriasis. J Am Acad Dermatol 2007; 52: 172-173.
49. Kruege GG, Langley RG, Leonardi C, et al. CNTO 1275 Psoriasis Study Group. CNTO 1275 Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356: 580-592.
50. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007; 204: 3183-3194.
51. Kohno M, Tsutsumi A, Matsui H, et al. Interleukin-17 gene expression in patients with rheumatoid arthritis. Mod Rheumatol 2008; 18: 15-22.
52. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 2008; 205: 2491-2497.
53. Billich A. Drug evaluation: Apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency. IDrugs 2007; 10: 53-59.
54. Wada Y, Lu R, Zhou D, et al. Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood 2007; 109: 1156-1164.
55. Keino H, Watanabe T, Sato Y, Niikura M, Wada Y, Okada AA. Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. Arthritis Res Ther 2008; 10: R122.
56. Klemann C, Je Raveney B, Oki S, Yamamura T. Retinoid signals and Th17-mediated pathology. Nihon Rinsho Meneki Gakkai Kaishi 2009; 32: 20-28.
57. Elias KM, Laurence A, Davidson TS, et al. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood 2008; 111: 1013-1020.
58. Mucida D, Park Y, Kim G, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007; 317: 256-260.
59. Xiao S, Jin H, Korn T, et al. Retinoic acid increases FoXp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-b-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol 2008; 181: 2277-2284.
60. Lemos HP, Grespan R, Vieira SM, et al. Selected natural and synthetic retinoids impair CCR7- and CXCR4-dependent cell migration in vitro and in vivo. J Leukoc Biol 2008; 84: 871-879.
61. Marusic S, Thakker P, Pelker JW, et al. Blockade of cytosolic phospholipase A2 alpha prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses. J Neuroimmunol 2008; 204: 29-37.
62. Chizzolini C, Chicheportiche R, Alvarez M, de Rham C, Roux-Lombard P. Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion. Blood 2008; 112: 3696-703.
63. Ferrari-Lacraz S, Dayer JM. In vitro Differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells. J Immunol 2008; 181: 721-735.
64. Khayrullina T, Yen JH, Jing H, Ganea D. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23 - >IL-17 axis. J Immunol 2007; 178: 8138-147.
65. Sheibanie AF, Yen JH, Khayrullina T, et al. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med 2009 [Epub ahead of print].
66. Boniface K, Bak-Jensen KS, Li Y, et al. Prostaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNγ production. Proc Natl Acad Sci USA 2009 [Epub ahead of print].
67. Villablanca EJ, Zhou D, Valentinis B, et al. Prostaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNγ production. Proc Natl Acad Sci USA 2009 [Epub ahead of print].
68. Haworth O, Cernadas M, Yang R, Serhan CN, Levy BD. Resolvin E1 regulates interleukin 23, interferon-g and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat Immunol 2008; 9: 873-879.
69. Zhang X, Markovic-Plese S. Statins' immunomodulatory potential against Th17 cell-mediated autoimmune response. Immunol Res 2008; 41(3): 165-174.
70. Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol 2008; 180(10): 6988-996.
71. Murphy DM, Forrest IA, Corris PA, et al. Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients. Am J Physiol Lung Cell Mol Physiol 2008; 294: L592-L595.
72. Shirinsky IV, Zheltova OI, Solovyova NY, Kozlov VA, Shirinsky VS. Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment. Scand J Rheumatol 2009; 38(1): 23-27.
73. Imamura M, Okunishi K, Ohtsu H, et al. Pravastatin attenuates allergic airway inflammation by suppressing antigen sensitisation, interleukin 17 production and antigen presentation in the lung. Thorax 2009; 64(1): 44-49.
74. Liao JJ, Huang MC, Goetzl EJ. Cutting edge: Alternative signaling of Th17 cell development by sphingosine 1-phosphate. J Immunol 2007; 178(9): 5425-428.
75. Michel ML, Keller AC, Paget C, et al. Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med 2007; 204: 995-1001.
76. Lee KA, Kang MH, Lee YS, et al. A distinct subset of natural killer T cells produces IL-17, contributing to airway infiltration of neutrophils but not to airway hyperreactivity. Cell Immunol 2008; 251: 50-55.
77. Michel ML, Mendes-da-Cruz D, Keller AC, et al. Critical role of ROR-gammat in a new thymic pathway leading to IL-17-producing invariant NKT cell differentiation. Proc Natl Acad Sci USA 2008; 105: 19845-850.
78. Hughes T, Becknell B, McClory S, et al. Stage three immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH17 cytokine interleukin-22. Blood 2009 [Epub ahead of print].
79. Ashkar AA, Reid S, Verdu EF, Zhang K, Coombes BK. Interleukin-15 and NK1.1+ cells provide innate protection against acute Salmonella enterica serovar Typhimurium infection in the gut and in systemic tissues. Infect Immun 2009; 77: 214-222.
80. Cho ML, Ju JH, Kim KW, et al. Cyclosporine A inhibits IL-15-induced IL-17 production in CD4+ T cells via down-regulation of PI3K/Akt and NF-kappaB. Immunol Lett 2007; 108: 88-96.
81. Haider AS, Lowes MA, Suárez-Fariñas M, et al. Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 2008; 180: 1913-1920.
82. Kopf H, de la Rosa GM, Howard OM, Chen X. Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int Immunopharmacol 2007; 7: 1819-1824.
83. Yang K, Wen J, Liu X, et al. Inhibitory effect of rapamycin and dexamethasone on production of IL-17 and IFN-gamma in Vogt-Koyanagi-Harada patients. Br J Ophthalmol 2009; 93(2): 249-253.
84. Momcilović M, Miljković Z, Popadić D, et al. Methylprednisolone inhibits interleukin-17 and interferon-gamma expression by both naive and primed T cells. BMC Immunol 2008; 9: 47.
85. McKinley L, Alcorn JF, Peterson A, et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyper-responsiveness in mice. J Immunol 2008; 181: 4089-4097.
86. Ivanenkov YA, Balakin KV, Tkachenko SE. New approaches to the treatment of inflammatory disease: Focus on small-molecule inhibitors of signal transduction pathways. Drugs R D 2008; 9(6): 397-434.
87. Peifer C, Wagner G, Laufer S. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. Curr Top Med Chem 2006; 6: 113-149.
88. Wagner G, Laufer S. Small molecular anti-cytokine agents. Med Res Rev 2006; 26(1): 1-62.
89. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006; 174(5): 566-570.
90. Vanaudenaerde BM, Wuyts WA, Geudens N, et al. Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells. Am J Transplant 2007; 7: 76-82.
91. Veldhoen M, Hirota K, Westendorf AM, et al. The aryl hydrocarbon receptor links TH-17-cell-mediated-autoimmunity to envirovmental toxins. Nature 2008; 453: 46-47.
92. Ho PP, Steinman L. The aryl hydrocarbon receptor: A regulator of Th17 and Treg cell development in disease. Cell Res 2008; 18: 605-608.
93. Kimura A, Naka T, Nohara K, et al. Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci USA 2008; 105: 9721-9726.
94. Veldhoen M, Hirota K, Christensen J, et al. Natural agonist for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 2009; 206: 43-49.